Fintepla (fenfluramine) is a small molecule pharmaceutical. Fenfluramine was first approved as Fintepla on 2020-06-25. It is used to treat autistic disorder, bulimia, and obesity in the USA. It has been approved in Europe to treat myoclonic epilepsies. It is known to target tryptophan 5-hydroxylase 1 and tryptophan 5-hydroxylase 2. Fintepla's patents are valid until 2039-10-22 (FDA).
|Indication||autistic disorder, bulimia, myoclonic epilepsies, obesity|